NeOnc Eliminates Major Dilution Risk as Clinical Story Accelerates
NeOnc Technologies redeemed all 6,000 outstanding shares of its Series A Convertible Preferred Stock for $6 million in cash, issuing zero common shares in the process. The redemption was funded by a $15 million registered direct offering announced days earlier and closes the door on a conversion feature that would have allowed holders to convert at 80% of the lowest closing price over the prior five trading days (with a $1 floor) once the four-month redemption window lapsed.
Key figures
- Neo100 pfs 6mo
- 48.9%
- Neo212 rp2d mg
- 610
- Conversion terms
- 80% of lowest closing price during preceding 5 trading days, subject to $1 floor
- Redemption cost usd
- 6000000
- Neo100 pfs benchmark
- 20%
- Neo100 median os months
- 26.09
- Preferred shares redeemed
- 6000
- Registered direct offering usd
- 15000000
- Common shares issued for redemption
- 0
- Original preferred gross proceeds usd
- 5000000
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.